Beyond artificial tears: a new era in dry eye disease management – a review article
DOI:
https://doi.org/10.12775/JEHS.2026.88.69377Keywords
dry eye disease (DED), tear film homeostasis, meibomian gland dysfunction (MGD), current concepts in dry eye disease, emerging therapies for dry eye disease, personalized therapy in dry eye diseaseAbstract
Dry eye disease (DED) is a prevalent and increasingly recognized disorder of the ocular surface that poses a significant clinical and public health challenge worldwide. Its complex and heterogeneous nature reflects the interplay of tear film instability, inflammation, epithelial dysfunction, and neurosensory abnormalities. The evolving understanding of DED pathophysiology has led to substantial changes in diagnostic criteria and therapeutic paradigms, shifting from purely symptomatic management toward mechanism-based and individualized approaches. Ongoing advances in molecular biology, immunology, and biomedical technology continue to reshape the therapeutic landscape of DED. In light of the growing clinical burden and the evolving understanding of DED as a complex, multifactorial disorder of the ocular surface characterized by loss of tear film homeostasis, hyperosmolarity, inflammation, and neurosensory abnormalities—as defined by the Tear Film & Ocular Surface Society in the TFOS DEWS III report—the purpose of this study was to comprehensively review the current evidence regarding DED pathophysiology, risk factors, classification, diagnostic algorithms, and contemporary therapeutic strategies, with particular emphasis on mechanism-based and emerging treatments.
References
1. Wolffsohn JS, Benítez-Del-Castillo JM, Loya-Garcia D, et al. TFOS DEWS III: Diagnostic Methodology. Am J Ophthalmol. 2025;279:387-450. doi: https://doi.org/10.1016/j.ajo.2025.05.033.
2. Mittal R, Patel S, Galor A. Alternative therapies for dry eye disease. Curr Opin Ophthalmol. 2021;32(4):348-361. doi: https://doi.org/10.1097/icu.0000000000000768.
3. O'Neil EC, Henderson M, Massaro-Giordano M, Bunya VY. Advances in dry eye disease treatment. Curr Opin Ophthalmol. 2019;30(3):166-178. doi: https://doi.org/10.1097/ICU.0000000000000569.
4. Sheppard J, Shen Lee B, Periman LM. Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists. Ann Med. 2023;55(1):241-252. doi: https://doi.org/10.1080/07853890.2022.2157477.
5. Wirta D, Vollmer P, Paauw J, et al. Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The ONSET-2 Phase 3 Randomized Trial. Ophthalmology. 2022;129(4):379-387. doi: https://doi.org/10.1016/j.ophtha.2021.11.004.
6. Barabino S, Benitez-Del-Castillo JM, Fuchsluger T, et al. Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification. Eur Rev Med Pharmacol Sci. 2020;24(17):8642-8652. doi: https://doi.org/10.26355/eurrev_202009_22801.
7. Rolando M, Merayo-Lloves J. Management Strategies for Evaporative Dry Eye Disease and Future Perspective. Curr Eye Res. 2022;47(6):813-823. doi: https://doi.org/10.1080/02713683.2022.2039205.
8. Stapleton F, Argüeso P, Asbell P, et al. TFOS DEWS III: Digest. Am J Ophthalmol. 2025;279:451-553. doi: https://doi.org/10.1016/j.ajo.2025.05.040.
9. Mohamed HB, Abd El-Hamid BN, Fathalla D, Fouad EA. Current trends in pharmaceutical treatment of dry eye disease: A review. Eur J Pharm Sci. 2022;175:106206. doi: https://doi.org/10.1016/j.ejps.2022.106206.
10. Barbosa Ribeiro B, Marta A, Ponces Ramalhão J, Marques JH, Barbosa I. Pulsed Light Therapy in the Management of Dry Eye Disease: Current Perspectives. Clin Ophthalmol. 2022;16:3883-3893. Published 2022 Nov 24. doi: https://doi.org/10.2147/opth.s349596.
11. Suwal A, Hao JL, Zhou DD, Liu XF, Suwal R, Lu CW. Use of Intense Pulsed Light to Mitigate Meibomian Gland Dysfunction for Dry Eye Disease. Int J Med Sci. 2020;17(10):1385-1392. Published 2020 Jun 1. doi: https://doi.org/10.7150/ijms.44288
12. Tashbayev B, Yazdani M, Arita R, Fineide F, Utheim TP. Intense pulsed light treatment in meibomian gland dysfunction: A concise review. Ocul Surf. 2020;18(4):583-594. doi: https://doi.org/10.1016/j.jtos.2020.06.002.
13. Dell SJ. Intense pulsed light for evaporative dry eye disease. Clin Ophthalmol. 2017;11:1167-1173. Published 2017 Jun 20. doi: https://doi.org/10.2147/opth.s139894.
14. Narang P, Donthineni PR, D'Souza S, Basu S. Evaporative dry eye disease due to meibomian gland dysfunction: Preferred practice pattern guidelines for diagnosis and treatment. Indian J Ophthalmol. 2023;71(4):1348-1356. doi: https://doi.org/10.4103/ijo.ijo_2841_22.
15. Wu Y, Mou Y, Zhang Y, et al. Efficacy of Intense Pulsed Light Combined Blood Extract Eye Drops for Treatment of Nociceptive Pain in Dry Eye Patients. J Clin Med. 2022;11(5):1312. Published 2022 Feb 27. doi: https://doi.org/10.3390/jcm11051312.
16. Jones L, Craig JP, Markoulli M, et al. TFOS DEWS III: Management and Therapy. Am J Ophthalmol. 2025;279:289-386. doi: https://doi.org/10.1016/j.ajo.2025.05.039.
17. Huang R, Su C, Fang L, Lu J, Chen J, Ding Y. Dry eye syndrome: comprehensive etiologies and recent clinical trials. Int Ophthalmol. 2022;42(10):3253-3272. doi: https://doi.org/10.1007/s10792-022-02320-7.
18. Zemanová M. DRY EYE DISEASE. A REVIEW. SYNDROM SUCHÉHO OKA. přehled. Cesk Slov Oftalmol. 2021;77(3):107–119. doi: https://doi.org/10.31348/2020/29.
19. Gupta PK, Toyos R, Sheppard JD, et al. Tolerability of Current Treatments for Dry Eye Disease: A Review of Approved and Investigational Therapies. Clin Ophthalmol. 2024;18:2283-2302. Published 2024 Aug 16. doi: https://doi.org/10.2147/opth.s465143.
20. Zhang D, Chen T, Liang Q, et al. A first-in-human, prospective pilot trial of umbilical cord-derived mesenchymal stem cell eye drops therapy for patients with refractory non-Sjögren's and Sjögren's syndrome dry eye disease. Stem Cell Res Ther. 2025;16(1):202. Published 2025 Apr 23. doi: https://doi.org/10.1186/s13287-025-04292-8.
21. Tauber J, Berdy GJ, Wirta DL, Krösser S, Vittitow JL; GOBI Study Group. NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study. Ophthalmology. 2023;130(5):516-524. doi: https://doi.org/10.1016/j.ophtha.2022.12.021
22. Protzko EE, Segal BA, Korenfeld MS, Krösser S, Vittitow JL. Long-Term Safety and Efficacy of Perfluorohexyloctane Ophthalmic Solution for the Treatment of Patients With Dry Eye Disease: The KALAHARI Study. Cornea. 2024;43(9):1100-1107. doi: https://doi.org/10.1097/ico.0000000000003418.
23. Sheppard JD, Kurata F, Epitropoulos AT, Krösser S, Vittitow JL; MOJAVE Study Group. NOV03 for Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction: The Randomized Phase 3 MOJAVE Study. Am J Ophthalmol. 2023;252:265-274. doi: https://doi.org/10.1016/j.ajo.2023.03.008.
24. Periman LM, Perez VL, Saban DR, Lin MC, Neri P. The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options. J Ocul Pharmacol Ther. 2020;36(3):137-146. doi: https://doi.org/10.1089/jop.2019.0060.
25. McCann P, Kruoch Z, Lopez S, Malli S, Qureshi R, Li T. Interventions for Dry Eye: An Overview of Systematic Reviews. JAMA Ophthalmol. 2024;142(1):58-74. doi: https://doi.org/10.1001/jamaophthalmol.2023.5751.
26. Baiula M, Spampinato S. Experimental Pharmacotherapy for Dry Eye Disease: A Review. J Exp Pharmacol. 2021;13:345-358. Published 2021 Mar 23. doi: https://doi.org/10.2147/jep.s237487.
27. Pattar GR, Wirta D, Jerkins G, et al. Acoltremon Ophthalmic Solution 0.003% for Signs and Symptoms of Dry Eye Disease: Results of Phase 3 Pivotal COMET-2 and COMET-3 Studies. Ophthalmology. Published online September 30, 2025. doi: https://doi.org/10.1016/j.ophtha.2025.09.018.
28. Lambiase A, Sullivan BD, Schmidt TA, et al. A Two-Week, Randomized, Double-masked Study to Evaluate Safety and Efficacy of Lubricin (150 μg/mL) Eye Drops Versus Sodium Hyaluronate (HA) 0.18% Eye Drops (Vismed®) in Patients with Moderate Dry Eye Disease. Ocul Surf. 2017;15(1):77-87. doi: https://doi.org/10.1016/j.jtos.2016.08.004.
29. Tauber J, Laurie GW, Parsons EC, Odrich MG; Lacripep Study Group; Lacripep Study Group. Lacripep for the Treatment of Primary Sjögren-Associated Ocular Surface Disease: Results of the First-In-Human Study. Cornea. 2023;42(7):847-857. doi: https://doi.org/10.1097/ico.0000000000003091.
30. Sosne G, Kleinman HK, Springs C, Gross RH, Sung J, Kang S. 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. Int J Mol Sci. 2022;24(1):554. Published 2022 Dec 29. doi: https://doi.org/10.3390/ijms24010554
31. RegeneRx Biopharmaceuticals, Inc. RegeneRx JV Presents Results of Phase 2b/3 (ARISE-1) Dry Eye Trial at ARVO 2017. Published May 9, 2017. Accessed February 23, 2026. https://www.regenerx.com/2017-05-09-RegeneRx-JV-Presents-Results-of-Phase-2b-3-ARISE-1-Dry-Eye-Trial-at-ARVO-2017
32. RegeneRx Biopharmaceuticals, Inc. RegeneRx JV Announces Results of ARISE-2 Dry Eye Trial. Published October 31, 2017. Accessed February 23, 2026. https://www.regenerx.com/2017-10-31-RegeneRx-JV-Announces-Results-of-ARISE-2-Dry-Eye-Trial
33. RegeneRx Biopharmaceuticals, Inc. RegeneRx Reports Topline Results of ARISE-3 Dry Eye Trial. Published March 18, 2021. Accessed February 23, 2026. https://www.regenerx.com/2021-03-18-RegeneRx-Reports-Topline-Results-of-ARISE-3-Dry-Eye-Trial
34. Brzheskiy VV, Efimova EL, Vorontsova TN, et al. Results of a Multicenter, Randomized, Double-Masked, Placebo-Controlled Clinical Study of the Efficacy and Safety of Visomitin Eye Drops in Patients with Dry Eye Syndrome. Adv Ther. 2015;32(12):1263-1279. doi: https://doi.org/10.1007/s12325-015-0273-6.
35. Mitotech Pharma and Essex Bio-Technology. Mitotech and Essex Bio-Technology Announce Positive Results of VISTA-2 Phase 3 Clinical Study in Dry Eye Disease. Published [date not available]. Accessed February 23, 2026. https://www.mitotechpharma.com/news/mitotech-and-essex-bio-technology-announce-positive-results-of-vista-2-phase-3-clinical-study-in-dry-eye-disease
36. Chen HC, Chen ZY, Wang TJ, et al. Herbal Supplement in a Buffer for Dry Eye Syndrome Treatment. Int J Mol Sci. 2017;18(8):1697. Published 2017 Aug 3. doi: https://doi.org/10.3390/ijms18081697.
37. Li Q, Wu X, Xin S, Wu X, Lan J. Preparation and characterization of a naringenin solubilizing glycyrrhizin nanomicelle ophthalmic solution for experimental dry eye disease. Eur J Pharm Sci. 2021;167:106020. doi: https://doi.org/10.1016/j.ejps.2021.106020.
38. Hassan A, Balal S, Cook E, et al. Finger-Prick Autologous Blood (FAB) Eye Drops for Dry Eye Disease: Single Masked Multi-Centre Randomised Controlled Trial. Clin Ophthalmol. 2022;16:3973-3979. Published 2022 Dec 2. doi: https://doi.org/10.2147/opth.s384586.
39. Vazirani J, Sridhar U, Gokhale N, Doddigarla VR, Sharma S, Basu S. Autologous serum eye drops in dry eye disease: Preferred practice pattern guidelines. Indian J Ophthalmol. 2023;71(4):1357-1363. doi: https://doi.org/10.4103/ijo.ijo_2756_22.
40. Holland EJ, Luchs J, Karpecki PM, et al. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3). Ophthalmology. 2017;124(1):53-60. doi: https://doi.org/10.1016/j.ophtha.2016.09.025.
41. Demolin L, Es-Safi M, Soyfoo MS, Motulsky E. Intense Pulsed Light Therapy in the Treatment of Dry Eye Diseases: A Systematic Review and Meta-Analysis. J Clin Med. 2023;12(8):3039. Published 2023 Apr 21. doi: https://doi.org/10.3390/jcm12083039.
42. Pérez-Silguero MA, Pérez-Silguero D, Rivero-Santana A, Bernal-Blasco MI, Encinas-Pisa P. Combined Intense Pulsed Light and Low-Level Light Therapy for the Treatment of Dry Eye: A Retrospective Before-After Study with One-Year Follow-Up. Clin Ophthalmol. 2021;15:2133-2140. Published 2021 May 21. doi: https://doi.org/10.2147/opth.s307020.
43. Solomos L, Bouthour W, Malclès A, Thumann G, Massa H. Meibomian Gland Dysfunction: Intense Pulsed Light Therapy in Combination with Low-Level Light Therapy as Rescue Treatment. Medicina (Kaunas). 2021;57(6):619. Published 2021 Jun 14. doi: https://doi.org/10.3390/medicina57060619.
44. Stonecipher K, Abell TG, Chotiner B, Chotiner E, Potvin R. Combined low level light therapy and intense pulsed light therapy for the treatment of meibomian gland dysfunction. Clin Ophthalmol. 2019;13:993-999. Published 2019 Jun 11. doi: https://doi.org/10.2147/opth.s213664.
45. Qin G, Chen J, Li L, et al. Efficacy of intense pulsed light therapy on signs and symptoms of dry eye disease: A meta-analysis and systematic review. Indian J Ophthalmol. 2023;71(4):1316-1325. doi: https://doi.org/10.4103/ijo.ijo_2987_22.
46. Qin G, Chen J, Li L, et al. Managing Severe Evaporative Dry Eye with Intense Pulsed Light Therapy. Ophthalmol Ther. 2023;12(2):1059-1071. doi: https://doi.org/10.1007/s40123-023-00649-5.
47. Toyos R, Desai NR, Toyos M, Dell SJ. Intense pulsed light improves signs and symptoms of dry eye disease due to meibomian gland dysfunction: A randomized controlled study. PLoS One. 2022;17(6):e0270268. Published 2022 Jun 23. doi: https://doi.org/10.1371/journal.pone.0270268.
48. Garg D, Daigavane S. Photobiomodulation in Ophthalmology: A Comprehensive Review of Bench-to-Bedside Research and Clinical Integration. Cureus. 2024;16(9):e69651. Published 2024 Sep 18. doi: https://doi.org/10.7759/cureus.69651
49. Goo H, Lee YJ, Lee S, Hong N. The Anti-Inflammatory Effect of Multi-Wavelength Light-Emitting Diode Irradiation Attenuates Dry Eye Symptoms in a Scopolamine-Induced Mouse Model of Dry Eye. Int J Mol Sci. 2023;24(24):17493. Published 2023 Dec 14. doi: https://doi.org/10.3390/ijms242417493.
50. Park Y, Kim H, Kim S, Cho KJ. Effect of low-level light therapy in patients with dry eye: a prospective, randomized, observer-masked trial. Sci Rep. 2022;12(1):3575. Published 2022 Mar 4. doi: https://doi.org/10.1038/s41598-022-07427-6.
51. Giannaccare G, Vaccaro S, Pellegrini M, et al. Serial Sessions of a Novel Low-Level Light Therapy Device for Home Treatment of Dry Eye Disease. Ophthalmol Ther. 2023;12(1):459-468. doi: https://doi.org/10.1007/s40123-022-00619-3.
52. Di Marino M, Conigliaro P, Aiello F, et al. Combined Low-Level Light Therapy and Intense Pulsed Light Therapy for the Treatment of Dry Eye in Patients with Sjögren's Syndrome. J Ophthalmol. 2021;2021:2023246. Published 2021 Jun 10. doi: https://doi.org/10.1155/2021/2023246.
53. Marques JH, Marta A, Baptista PM, et al. Low-Level Light Therapy in Association with Intense Pulsed Light for Meibomian Gland Dysfunction. Clin Ophthalmol. 2022;16:4003-4010. Published 2022 Dec 6. doi: https://doi.org/10.2147/opth.s384360.
54. Warren NA, Maskin SL. Review of Literature on Intraductal Meibomian Gland Probing with Insights from the Inventor and Developer: Fundamental Concepts and Misconceptions. Clin Ophthalmol. 2023;17:497-514. Published 2023 Feb 8. doi: https://doi.org/10.2147/opth.s390085.
55. Gupta PK, Holland EJ, Hovanesian J, et al. TearCare for the Treatment of Meibomian Gland Dysfunction in Adult Patients With Dry Eye Disease: A Masked Randomized Controlled Trial. Cornea. 2022;41(4):417-426. doi: https://doi.org/10.1097/ico.0000000000002837.
56. Ayres BD, Bloomenstein MR, Loh J, et al. A Randomized, Controlled Trial Comparing Tearcare® and Cyclosporine Ophthalmic Emulsion for the Treatment of Dry Eye Disease (SAHARA). Clin Ophthalmol. 2023;17:3925-3940. Published 2023 Dec 18. doi: https://doi.org/10.2147/opth.s442971.
57. Beining MW, Magnø MS, Moschowits E, et al. In-office thermal systems for the treatment of dry eye disease. Surv Ophthalmol. 2022;67(5):1405-1418. doi: https://doi.org/10.1016/j.survophthal.2022.02.007.
58. Gomez ML, Afshari NA, Gonzalez DD, Cheng L. Effect of Thermoelectric Warming Therapy for the Treatment of Meibomian Gland Dysfunction. Am J Ophthalmol. 2022;242:181-188. doi: https://doi.org/10.1016/j.ajo.2022.06.013.
59. Li S, Yang K, Wang J, et al. Effect of a Novel Thermostatic Device on Meibomian Gland Dysfunction: A Randomized Controlled Trial in Chinese Patients. Ophthalmol Ther. 2022;11(1):261-270. doi: https://doi.org/10.1007/s40123-021-00431-5.
60. Magno MS, Olafsson J, Beining M, et al. Chambered warm moist air eyelid warming devices - a review. Acta Ophthalmol. 2022;100(5):499-510. doi: https://doi.org/10.1111/aos.15052.
61. Wang DH, Guo H, Xu W, Liu XQ. Efficacy and safety of the disposable eyelid warming masks in the treatment of dry eye disease due to Meibomian gland dysfunction. BMC Ophthalmol. 2024;24(1):376. Published 2024 Aug 26. doi: https://doi.org/10.1186/s12886-024-03642-z.
62. Wang MT, Jaitley Z, Lord SM, Craig JP. Comparison of Self-applied Heat Therapy for Meibomian Gland Dysfunction. Optom Vis Sci. 2015;92(9):e321-e326. doi: https://doi.org/10.1097/opx.0000000000000601.
63. Ballesteros-Sánchez A, Gargallo-Martínez B, Gutiérrez-Ortega R, Sánchez-González JM. Eyelid Exfoliation Treatment Efficacy and Safety in Dry Eye Disease, Blepharitis, and Contact Lens Discomfort Patients: A Systematic Review. Asia Pac J Ophthalmol (Phila). 2023;12(3):315-325. doi: https://doi.org/10.1097/apo.0000000000000607.
64. Schanzlin D, Olkowski J, Hosten T, Gunderson E. Efficacy of self-administration of a personal mechanical eyelid device for the treatment of dry eye disease, blepharitis, and meibomian gland disease. J Dry Eye Dis. 2020;3(1). doi: https://doi.org/10.22374/jded.v3i1.25.
65. Ji MH, Moshfeghi DM, Periman L, et al. Novel Extranasal Tear Stimulation: Pivotal Study Results. Transl Vis Sci Technol. 2020;9(12):23. Published 2020 Nov 17. doi: https://doi.org/10.1167/tvst.9.12.23.
66. Ballesteros-Sánchez A, Borroni D, De-Hita-Cantalejo C, et al. Efficacy of bilateral OC-01 (varenicline solution) nasal spray in alleviating signs and symptoms of dry eye disease: A systematic review. Cont Lens Anterior Eye. 2024;47(1):102097. doi: https://doi.org/10.1016/j.clae.2023.102097.
67. Torkildsen GL, Pattar GR, Jerkins G, Striffler K, Nau J. Efficacy and Safety of Single-dose OC-02 (Simpinicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The PEARL Phase II Randomized Trial. Clin Ther. 2022;44(9):1178-1186. doi: https://doi.org/10.1016/j.clinthera.2022.07.006
68. Qiu SX, Fadel D, Hui A. Scleral Lenses for Managing Dry Eye Disease in the Absence of Corneal Irregularities: What Is the Current Evidence?. J Clin Med. 2024;13(13):3838. Published 2024 Jun 29. doi: https://doi.org/10.3390/jcm13133838.
69. Shen G, Qi Q, Ma X. Effect of Moisture Chamber Spectacles on Tear Functions in Dry Eye Disease. Optom Vis Sci. 2016;93(2):158-164. doi: https://doi.org/10.1097/opx.0000000000000778.
70. Ogawa M, Dogru M, Toriyama N, Yamaguchi T, Shimazaki J, Tsubota K. Evaluation of the Effect of Moist Chamber Spectacles in Patients With Dry Eye Exposed to Adverse Environment Conditions. Eye Contact Lens. 2018;44(6):379-383. doi: https://doi.org/10.1097/icl.0000000000000431.
71. Hopkinson A, Figueiredo FC. A Narrative Review of Amniotic Membrane Transplantation in Ocular Surface Repair: Unveiling the Immunoregulatory Pathways for Timely Intervention. Ophthalmol Ther. 2025;14(7):1385-1409. doi: https://doi.org/10.1007/s40123-025-01143-w.
72. Eyes on Eyecare. Ultimate Guide to Biologics for Optometrists. Published [date not available]. Accessed February 23, 2026. https://eyesoneyecare.com/resources/ultimate-guide-to-biologics-for-optometrists/
73. McDonald MB, Sheha H, Tighe S, et al. Treatment outcomes in the DRy Eye Amniotic Membrane (DREAM) study. Clin Ophthalmol. 2018;12:677-681. Published 2018 Apr 9. doi: https://doi.org/10.2147/opth.s162203.
74. Murri MS, Moshirfar M, Birdsong OC, Ronquillo YC, Ding Y, Hoopes PC. Amniotic membrane extract and eye drops: a review of literature and clinical application. Clin Ophthalmol. 2018;12:1105-1112. Published 2018 Jun 18. doi: https://doi.org/10.2147/opth.s165553.
75. Yeu E, Goldberg DF, Mah FS, et al. Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease. Clin Ophthalmol. 2019;13:887-894. Published 2019 May 27. doi: https://doi.org/10.2147/OPTH.S203510.
76. Marta A, Baptista PM, Heitor Marques J, et al. Intense Pulsed Plus Low-Level Light Therapy in Meibomian Gland Dysfunction. Clin Ophthalmol. 2021;15:2803-2811. Published 2021 Jun 28. doi: https://doi.org/10.2147/opth.s318885.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Jakub Mikołaj Sapikowski, Agata Juchniewicz, Maria Janiszewska, Iga Kuba, Julita Jagodzińska, Mikołaj Góralczyk, Martyna Grześkowiak, Jakub Idziński, Anna Lubomska, Igor Jętasiewicz
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 17
Number of citations: 0
